Biotech Evommune and diagnostics startup BillionToOne will begin trading today, with venture investors avid to see public markets fully embrace the sector again.
Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering
BillionToOne （BLLN.US） IPO Overview
a molecular diagnostics company on a mission to make powerful and accessible genetic tests available to all, in its upsized initial public offering of 4.6 million shares of Class A common stock at a price to the public of $60 per share, generating approximately $273.1 million in aggregate gross proceeds. The shares began trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025.
BillionToOne （BLLN.US） officially listed on Nasdaq on Thursday
The stock surged sharply at the opening bell, closing up 81.57% for the day. Its market capitalization rapidly climbed to nearly $4.8 billion, making it a standout new listing that defied the market downturn amid the government shutdown.
BillionToOne （BLLN.US）Company Performance
Financial data shows that in the first half of the year ending June 30, the company’s revenue surged 82% year-over-year, with gross profit more than doubling, demonstrating robust commercialization capabilities and strong growth momentum. The strong reception of this IPO also reflects the capital market’s sustained interest in high-growth medical technology companies.